Market Overview

Rising Biosciences Receives FDA Clearance for TSW Pain Cream; Expedites Testing of CBD Only Variants of Cannophen™ and TSW Pain Cream Products

Share:

RBII Seeks Corporate Registration in Canada Alongside Country's Decision to Legalize Marijuana

Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



Analyses Biologiques et Chimiques
$RBII FDA APPROVAL



SANDUSKY, Ohio, Oct. 10, 2018 (GLOBE NEWSWIRE) --  via OTC PR WIRE – Rising Biosciences, Inc. (RBII) ("RBII" "the Company"), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that we have completed, and passed all testing requirements for the FDA on its over-the-counter version of its TSW Pain Cream, and the product is now moving into production.

"The past 30 days have been very exciting for our industry," states Rising Biosciences COO Arthur Hall.  " On September 21st, we completed our FDA testing on TSW, and last week, the DEA moved to place certain FDA approved CBD drugs down from Schedule I to Schedule V.  It is the first time the agency has lowered any type of cannabis from Schedule 1, indicating the agency's recognition of Cannabidiol as a viable medical treatment. Rising Biosciences is looking forward to working with the Canadian testing company ABICH Inc., who completed the FDA testing on our over-the-counter version of TSW Pain Cream for our testing needs on the CBD only variants of Cannophen and TSW Pain Cream."

As well, on October 17th, 2018, Marijuana becomes legal in Canada as a result of ‘The Cannabis Act', passed on June 3rd, 2018, marking Canada as the first G7 country to legalize Marijuana.  Rising Biosciences has decided to seek registration as a foreign corporation in Canada to assertively expand operations there in wake of legalization. 

"This is a special time for the Company and its Shareholders," states Hall.  "We have taken the company from dedicated vision to a fully integrated R&D, manufacturing and distribution, and are now ready for market.  We are grateful for shareholder patience, and support through the monumental steps we've taken over the past year and a half, and we are now taking the Company to new heights with some major updates to follow."

$RBII on Twitter for LIVE company updates! www.twitter.com/risingindiausa

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/46f29819-17fd-49a0-9e3b-b04a0ec75c1f

http://www.globenewswire.com/NewsRoom/AttachmentNg/1c4a949f-6973-4f43-98a0-c26a51863318

http://www.globenewswire.com/NewsRoom/AttachmentNg/f6fc6671-dd18-4ab2-af0d-4d0406f93812

http://www.globenewswire.com/NewsRoom/AttachmentNg/2d567817-3181-4489-9ae7-944b628cdcb6

http://www.globenewswire.com/NewsRoom/AttachmentNg/7148f35c-8cc1-40e9-96ed-8f2540341541

http://www.globenewswire.com/NewsRoom/AttachmentNg/674bb1f3-161c-4d6f-ab8a-233fcd591d5c

http://www.globenewswire.com/NewsRoom/AttachmentNg/dceccdc7-60ba-4c38-8288-49220e93bee6

http://www.globenewswire.com/NewsRoom/AttachmentNg/d77a4296-d929-45d2-adb3-fe95acbfa7ad

2c23a2_4f0dc46bf9704b41acf94ab75ed49442-mv2_d_2406_1824_s_2.png

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com